Published in Amyotroph Lateral Scler Frontotemporal Degener on October 22, 2012
Assessment of Motor Units in Neuromuscular Disease. Neurotherapeutics (2017) 0.79
Evaluation of Motor Neuron Excitability by CMAP Scanning with Electric Modulated Current. Neurosci J (2015) 0.75
The Potential Role of Motor Unit Number Estimation as an Additional Diagnostic and Prognostic Value in Canine Neurology. Front Vet Sci (2015) 0.75
Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol (2008) 3.59
A clinical prognostic scoring system for Guillain-Barré syndrome. Lancet Neurol (2007) 2.73
The natural course of non-classic Pompe's disease; a review of 225 published cases. J Neurol (2005) 2.39
Residual fatigue in Guillain-Barre syndrome is related to axonal loss. Neurology (2013) 2.01
Diagnosis of Guillain-Barré syndrome and validation of Brighton criteria. Brain (2013) 1.93
Immunotherapy for Guillain-Barré syndrome: a systematic review. Brain (2007) 1.87
Pharmacokinetics of intravenous immunoglobulin and outcome in Guillain-Barré syndrome. Ann Neurol (2009) 1.67
Pulsed high-dose dexamethasone versus standard prednisolone treatment for chronic inflammatory demyelinating polyradiculoneuropathy (PREDICT study): a double-blind, randomised, controlled trial. Lancet Neurol (2010) 1.63
Guillain-Barré syndrome subtypes related to Campylobacter infection. J Neurol Neurosurg Psychiatry (2011) 1.62
Effects of hyperbaric treatment in cerebral air embolism on intracranial pressure, brain oxygenation, and brain glucose metabolism in the pig. Crit Care Med (2005) 1.59
Ultrasonographic assessment of longitudinal median nerve and hand flexor tendon dynamics in carpal tunnel syndrome. Muscle Nerve (2012) 1.57
Serum IgG levels in IV immunoglobulin treated chronic inflammatory demyelinating polyneuropathy. J Neurol Neurosurg Psychiatry (2013) 1.57
TDP-43 pathology in familial frontotemporal dementia and motor neuron disease without Progranulin mutations. Brain (2007) 1.55
Revised normative values for grip strength with the Jamar dynamometer. J Peripher Nerv Syst (2011) 1.48
Cone-rod dystrophy can be a manifestation of Danon disease. Graefes Arch Clin Exp Ophthalmol (2012) 1.45
Increased aortic stiffness and blood pressure in non-classic Pompe disease. J Inherit Metab Dis (2014) 1.44
Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database Syst Rev (2014) 1.40
Morphological changes in muscle tissue of patients with infantile Pompe's disease receiving enzyme replacement therapy. Muscle Nerve (2003) 1.32
High antibody titer in an adult with Pompe disease affects treatment with alglucosidase alfa. Mol Genet Metab (2010) 1.32
Fatigue: an important feature of late-onset Pompe disease. J Neurol (2007) 1.31
Corticosteroids for Guillain-Barré syndrome. Cochrane Database Syst Rev (2012) 1.20
Clinical features and predictors for disease natural progression in adults with Pompe disease: a nationwide prospective observational study. Orphanet J Rare Dis (2012) 1.19
Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database Syst Rev (2012) 1.17
Prediction of respiratory insufficiency in Guillain-Barré syndrome. Ann Neurol (2010) 1.16
Distinguishing acute-onset CIDP from Guillain-Barré syndrome with treatment related fluctuations. Neurology (2005) 1.15
TLR4-mediated sensing of Campylobacter jejuni by dendritic cells is determined by sialylation. J Immunol (2010) 1.14
Upper and extra-motoneuron involvement in early motoneuron disease: a diffusion tensor imaging study. Brain (2011) 1.13
Does a carpal tunnel syndrome predict an underlying disease? J Neurol Neurosurg Psychiatry (2006) 1.06
Diagnostic value of anti-GM1 ganglioside serology and validation of the INCAT-ELISA. J Neurol Sci (2005) 1.06
Ultrasound-guided near-nerve neurography for early evaluation of nerve regeneration. J Neurosci Methods (2008) 1.06
Impact of enzyme replacement therapy on survival in adults with Pompe disease: results from a prospective international observational study. Orphanet J Rare Dis (2013) 1.04
Effect of enzyme therapy and prognostic factors in 69 adults with Pompe disease: an open-label single-center study. Orphanet J Rare Dis (2012) 1.03
Survival and associated factors in 268 adults with Pompe disease prior to treatment with enzyme replacement therapy. Orphanet J Rare Dis (2011) 1.00
Comparison of weakness progression in inclusion body myositis during treatment with methotrexate or placebo. Ann Neurol (2002) 0.99
IgG Fc N-glycosylation in Guillain-Barré syndrome treated with immunoglobulins. J Proteome Res (2014) 0.98
Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database Syst Rev (2010) 0.96
Reproducibility of the CMAP scan. J Electromyogr Kinesiol (2010) 0.95
Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev (2013) 0.93
Perception of prognostic risk in patients with multiple sclerosis: the relationship with anxiety, depression, and disease-related distress. J Clin Epidemiol (2004) 0.92
Increased aortic stiffness in glycogenosis type 2 (Pompe's disease). Int J Cardiol (2006) 0.90
First experience with enzyme replacement therapy during pregnancy and lactation in Pompe disease. Mol Genet Metab (2011) 0.90
The electrophysiological muscle scan. Muscle Nerve (2007) 0.90
Subclass IgG to motor gangliosides related to infection and clinical course in Guillain-Barré syndrome. J Neuroimmunol (2008) 0.89
Understanding the consequences of chronic inflammatory demyelinating polyradiculoneuropathy from impairments to activity and participation restrictions and reduced quality of life: the ICE study. J Peripher Nerv Syst (2010) 0.89
Functional polymorphisms in LPS receptors CD14 and TLR4 are not associated with disease susceptibility or Campylobacter jejuni infection in Guillain-Barré patients. J Neuroimmunol (2004) 0.88
Anti-GM1 IgG antibodies induce leukocyte effector functions via Fcgamma receptors. Ann Neurol (2003) 0.87
Mannose-binding lectin contributes to the severity of Guillain-Barré syndrome. J Immunol (2006) 0.87
Chronic inflammatory demyelinating polyneuropathy disease activity status: recommendations for clinical research standards and use in clinical practice. J Peripher Nerv Syst (2010) 0.86
Chlamydia pneumoniae and the risk for exacerbation in multiple sclerosis patients. Ann Neurol (2003) 0.86
Optimal stimulation settings for CMAP scan registrations. J Brachial Plex Peripher Nerve Inj (2012) 0.86
Origin of ganglioside complex antibodies in Guillain-Barré syndrome. J Neuroimmunol (2007) 0.85
Severity of Guillain-Barré syndrome is associated with Fc gamma Receptor III polymorphisms. J Neuroimmunol (2005) 0.85
A new and fast approach towards sEMG decomposition. Med Biol Eng Comput (2013) 0.84
Challenges of clinical trial design when there is lack of clinical equipoise: use of a response-conditional crossover design. J Neurol (2011) 0.83
Motor unit number estimation using high-density surface electromyography. Clin Neurophysiol (2007) 0.83
A novel 16p locus associated with BSCL2 hereditary motor neuronopathy: a genetic modifier? Neurogenetics (2009) 0.83
Histological validation of ultrasound-guided neurography in early nerve regeneration. Muscle Nerve (2009) 0.82
Enzyme replacement therapy and fatigue in adults with Pompe disease. Mol Genet Metab (2013) 0.82
Continuous noninvasive monitoring of barbiturate coma in critically ill children using the Bispectral index monitor. Crit Care (2007) 0.82
Unmyelinated and myelinated skin nerve damage in Guillain-Barré syndrome: correlation with pain and recovery. Pain (2011) 0.82
The quick motor function test: a new tool to rate clinical severity and motor function in Pompe patients. J Inherit Metab Dis (2011) 0.82
Newer therapeutic options for chronic inflammatory demyelinating polyradiculoneuropathy. Drugs (2009) 0.82
Emerging drugs for Guillain-Barré syndrome. Expert Opin Emerg Drugs (2011) 0.82
Natural conduits for bridging a 15-mm nerve defect: comparison of the vein supported by muscle and bone marrow stromal cells with a nerve autograft. J Plast Reconstr Aesthet Surg (2012) 0.81
Analysing the favourable effects of physical exercise: relationships between physical fitness, fatigue and functioning in Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy. J Rehabil Med (2007) 0.81
ANO5 mutations in the Dutch limb girdle muscular dystrophy population. Neuromuscul Disord (2013) 0.81
Effect of glucocorticoid receptor gene polymorphisms in Guillain-Barré syndrome. J Peripher Nerv Syst (2009) 0.81
Mortality in Guillain-Barre syndrome. Neurology (2013) 0.81
Differentiation of hereditary spastic paraparesis from primary lateral sclerosis in sporadic adult-onset upper motor neuron syndromes. Arch Neurol (2009) 0.81
Genetic polymorphisms of macrophage-mediators in Guillain-Barré syndrome. J Neuroimmunol (2007) 0.81
Phenotypical variation within 22 families with Pompe disease. Orphanet J Rare Dis (2013) 0.81
Cortical excitability as a potential clinical marker of epilepsy: a review of the clinical application of transcranial magnetic stimulation. Int J Neural Syst (2014) 0.80
Corticosteroids for Guillain-Barré syndrome. Cochrane Database Syst Rev (2010) 0.80
Electrophysiology in chronic inflammatory demyelinating polyneuropathy with IGIV. Muscle Nerve (2009) 0.80
Automated EEG inter-burst interval detection in neonates with mild to moderate postasphyxial encephalopathy. Conf Proc IEEE Eng Med Biol Soc (2012) 0.80
Hearing in adults with Pompe disease. J Inherit Metab Dis (2011) 0.79
Assessment of transverse ultrasonographic parameters to optimize carpal tunnel syndrome diagnosis in a case-control study. Muscle Nerve (2013) 0.79
AChR deficiency due to epsilon-subunit mutations: two common mutations in the Netherlands. J Neurol (2009) 0.79
Susceptibility to Guillain-Barré syndrome is not associated with CD1A and CD1E gene polymorphisms. J Neuroimmunol (2008) 0.78
Significant reduction in neural adhesions after administration of the regenerating agent OTR4120, a synthetic glycosaminoglycan mimetic, after peripheral nerve injury in rats. J Neurosurg (2008) 0.78
Recurrences, vaccinations and long-term symptoms in GBS and CIDP. J Peripher Nerv Syst (2009) 0.78
Ictal nystagmus in a newborn baby after birth asphyxia. Clin EEG Neurosci (2006) 0.78
Selective digestive tract decontamination decreases time on ventilator in Guillain-Barré syndrome. Neurocrit Care (2011) 0.77
Electroencephalography during normotensive and hypertensive pregnancy: a systematic review. Obstet Gynecol Surv (2010) 0.77
Host factors determine anti-GM1 response following oral challenge of chickens with Guillain-Barré syndrome derived Campylobacter jejuni strain GB11. PLoS One (2010) 0.77
Fas polymorphisms are associated with the presence of anti-ganglioside antibodies in Guillain-Barre syndrome. J Neuroimmunol (2005) 0.77